Health & Benefits · In context

Medscheme actuaries warn gap cover can weaken medical schemes' cost controls

Four Medscheme actuaries told the Actuarial Society of South Africa's convention that gap cover undermines medical schemes' efforts to control costs, MedicalBrief reported. They said about 96% of gap cover claims come from tariff shortfalls, co-payments and sub-limits. Scheme contributions rose an average 8.1% a year from 2022 to 2026, against 5% inflation.

Illustration of two overlapping umbrellas with a small gap between them over a simple hospital building.
Illustration generated with AI for insurewire.org. Not a photograph of the event.

In context: this report covers a source published on 28 Oct 2026.

Actuaries from Medscheme, a South African medical scheme administrator, made the case at the Actuarial Society of South Africa convention in Cape Town, MedicalBrief reported on 28 October. The report describes the convention as recent but does not give its date. Allan Williams, an associate consultant, said gap cover "can undermine schemes' attempts to contain costs and ensure sustainability".

Gap cover pays members' shortfalls when a scheme does not meet a provider's full bill. The presenters said about 96% of its claims come from tariff shortfalls, co-payments and sub-limits. By paying those, they argued, it removes members' reason to use scheme networks, weakens schemes' bargaining power with providers and feeds a cycle of higher tariffs, benefit cuts and rising gap cover claims and premiums.

Their figures point to growing pressure on both products. An estimated 800,000 South Africans hold gap cover. Provider data for 2021 to 2026 show claimants with annual shortfalls above R50,000 rising about 13% a year and claim frequency growing more than 10% a year. In Medscheme's data, about 75% of hospital admissions in 2025 led to an out-of-pocket payment. Scheme contributions rose 8.1% a year on average from 2022 to 2026, against average inflation of 5%.

As remedies, the actuaries proposed that schemes and gap providers join provider arrangements that narrow tariff gaps without breaching competition law, and that gap cover reduce or exclude penalty co-payments, which apply when members skip designated networks, referrals or pre-authorisation. They also called for clear rules on which product pays first. MedicalBrief noted that reform of the Medical Schemes Act has been delayed.

Read the source

MedicalBrief ↗

News publisher · 28 Oct 2026

This is an original brief based on the linked publication. Company statements and forecasts are attributed to their source.

Continue reading

All stories →
Illustration

Health & Benefits

US judge strikes down CMS's narrow 'medically frail' definition for Medicaid work requirements

A federal judge in Massachusetts has vacated the narrow definition of "medically frail" that CMS wrote into its Medicaid work requirement rule, after 25 states and the District of Columbia sued. The ruling widens who can be exempt from the 80-hour monthly requirement that starts in 2027. Two other contested provisions stand, Healthcare Dive reported.

Illustration

Health & Benefits · In context

CVS sues CMS to overturn 2027 Medicare Advantage star ratings it says would cost about $2bn

CVS Health's Aetna unit has sued the US Centers for Medicare & Medicaid Services in a Georgia federal court over its 2027 Medicare Advantage star ratings. CVS says the ratings would cost it about $2bn in bonus payments in 2028. It wants 28 measures removed from the calculation, more than any other insurer has challenged, Healthcare Dive reported.

Illustration

Health & Benefits

US Labor Department finalises rule requiring PBMs to disclose fees to self-insured employer health plans

The US Department of Labor finalised a rule on 29 October that requires pharmacy benefit managers and their affiliated brokers and consultants to disclose fees and compensation to large employers' self-insured health plans. PBMs must reveal drugmaker rebates, spread margins and pharmacy clawbacks for the first time. The department projects drug cost savings of as much as $22bn over ten years.

The daily briefing